Reports
Sale
Africa Contraceptive Drugs and Devices Market Share, Report: By Product: Drugs, Devices, Others; By Gender: Male, Female; Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel and NGOs, Others; Market Dynamics: SWOT Analysis, Porter’s Five Forces Model; Supplier Landscape; 2024-2032
Africa Contraceptive Drugs and Devices Market Outlook
Africa contraceptive drugs and devices market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by the increasing number of unwanted pregnancies. The market growth is also driven by the rising initiatives by the government to create awareness among people in Africa.
Contraceptive Drugs and Devices: Introduction
Contraception is a procedure that includes the usage of drugs and devices depending on the preference and the severity of the patient. Contraception can be performed in an emergency and by choice, in both conditions there are plenty of options available in the market. These include condoms, diaphragms, cervical caps, sponges, vaginal rings, intrauterine devices (IUD), oral, contraceptive pills, injectables, and topical, among others. The oral pills can be used for birth control, but the administration regimen needs to be performed strictly. However, devices such as intrauterine devices are inserted in the uterus and a woman can prevent pregnancies for up to 10 years.
Africa Contraceptive Drugs and Devices Market Analysis
The market growth is driven by the increased initiative by the government to create awareness among people in Africa. With an increase in advancements including drugs and devices for contraception, the Africa contraceptive drugs and devices market growth is expected to follow an upward trajectory. Pharmaceutical companies in Africa are trying to innovate contraceptive products for their better utilization and enhanced efficacy. For example, a South African company has been working on a new version of vaginal rings to protect women against HIV. This dapivirine vaginal ring is a long-acting form of HIV prevention and has been approved for use in eleven sub-Saharan African nations, according to an international nonprofit organization. Some AIDS experts have said that these vaginal rings are expected to become cheaper in the longer run and will be easily available in the market. Such innovative developments may also provide ideas and knowledge to the developers to create something similar to help women against unwanted pregnancies, which will further contribute to the Africa contraceptive drugs and devices market share.
Additionally, the availability of condoms and other contraceptive drugs and devices has somehow curbed the restraining factors of the market. However, there is a crucial gap in the market which has provided the opportunity for pharmaceutical companies and NGOs to develop and create awareness against contraception among people, especially women. For example, the initiatives by the World Health Organization aspiring to achieve universal access and the realization of sexual and reproductive health services is an essential responsibility to fulfill the pledge of the 2030 Agenda for Sustainable Development that ‘no one will be left behind’ are expected to propel the market growth.
Africa Contraceptive Drugs and Devices Market Segmentations
Market Breakup by Product
- Drugs
- Oral Contraceptive Pills
- Injectable Contraceptives
- Topical Contraceptives
- Devices
- Condoms
- Diaphragms
- Cervical Caps
- Sponges
- Vaginal Ring
- Intra Uterine Devices (IUD)
- Others
- Others
Market Breakup by Gender
- Male
- Female
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Clinics
- Online Channel
- Public Channel and NGOs
- Others
Africa Contraceptive Drugs and Devices Market Overview
The growth of the market is driven by the increasing awareness about unwanted pregnancies and family planning in African regions. Africa is a low-economy, low-income region, lacking appropriate knowledge of family planning, resulting in unwanted pregnancies. Non-profit organizations, such as the World Health Organization (WHO), play a crucial role in developing knowledge in regions like Africa regarding contraceptive drugs and devices. Due to the increased initiatives by such organizations, awareness among people has substantially increased, and the market is witnessing increased demand, propelling the contraceptive drugs and devices market growth.
Furthermore, the market growth is driven by the rising prevalence of sexually transmitted diseases among the population. According to the data released by the National Institute of Health (NIH), South Africa has the largest count of people suffering from HIV (PLWH) of any country in the world. It is estimated by the Joint United Nations Programme on HIV/AIDS (UNAIDS), that prevalence in South Africa is 8 million with an incidence of 7 per 1000 among 15–49-year-olds. This data is more than enough to predict the growth in contraceptive drugs and devices market demand in the forecast period.
Africa Contraceptive Drugs and Devices Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the Africa contraceptive drugs and devices market are as follows:
- Merck & Co. Inc.
- Mylan N.V.
- Pfizer Inc.
- Bayer AG
- AbbVie
- Lupin Limited
- Teva Pharmaceutical Industries Ltd
- Medicines360
- Durex
- Mankind Pharma
- Johnson & Johnson
- Gabler Medical
- Sinapi Biomedical
- Church & Dwight
- CooperSurgical
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Gender |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Africa Contraceptive Drugs and Devices Market Overview
3.1 Africa Contraceptive Drugs and Devices Market Historical Value (2017-2023)
3.2 Africa Contraceptive Drugs and Devices Market Forecast Value (2024-2032)
4 Africa Contraceptive Drugs and Devices Market Landscape
4.1 Africa Contraceptive Drugs and Devices Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.2 Africa Contraceptive Drugs and Devices Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Gender
5 Africa Contraceptive Drugs and Devices Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Africa Contraceptive Drugs and Devices Market Segmentation
6.1 Africa Contraceptive Drugs and Devices Market by Product
6.1.1 Market Overview
6.1.2 Drugs
6.1.2.1 Oral Contraceptive Pills
6.1.2.2 Injectable Contraceptives
6.1.2.3 Topical Contraceptives
6.1.3 Devices
6.1.3.1 Condoms
6.1.3.2 Diaphragms
6.1.3.3 Cervical Caps
6.1.3.4 Sponges
6.1.3.5 Vaginal Ring
6.1.3.6 Intra Uterine Devices (IUD)
6.1.3.7 Others
6.1.4 Others
6.2 Africa Contraceptive Drugs and Devices Market by Gender
6.2.1 Market Overview
6.2.2 Male
6.2.3 Female
6.3 Africa Contraceptive Drugs and Devices Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacy
6.3.3 Retail Pharmacy
6.3.4 Clinics
6.3.5 Online Channel
6.3.6 Public Channel and NGOs
6.3.7 Others
7 Patent Analysis
7.1 Analysis by Type of Patent
7.2 Analysis by Publication year
7.3 Analysis by Issuing Authority
7.4 Analysis by Patent Age
7.5 Analysis by CPC Analysis
7.6 Analysis by Patent Valuation
7.7 Analysis by Key Players
8 Grants Analysis
8.1 Analysis by year
8.2 Analysis by Amount Awarded
8.3 Analysis by Issuing Authority
8.4 Analysis by Grant Application
8.5 Analysis by Funding Institute
8.6 Analysis by NIH Departments
8.7 Analysis by Recipient Organization
9 Clinical Trials Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
10 Funding & Investment Analysis
10.1 Analysis by Funding Instances
10.2 Analysis by Type of Funding
10.3 Analysis by Funding Amount
10.4 Analysis by Leading Players
10.5 Analysis by Leading Investors
10.6 Analysis by Geography
11 Partnership and Collaborations Analysis
11.1 Analysis by Partnership Instances
11.2 Analysis by Type of Partnership
11.3 Analysis by Leading Players
11.4 Analysis by Geography
12 Regulatory Framework
13 Supplier Landscape
13.1 Merck & Co. Inc.
13.1.1 Financial Analysis
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.1.5 Certifications
13.2 Mylan N.V.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Pfizer Inc.
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Bayer AG
13.4.1 Financial Analysis
13.4.2 Financial Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 AbbVie
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Lupin Limited
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Teva Pharmaceutical Industries Ltd
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Medicines360
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Durex
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Mankind Pharma
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Johnson & Johnson
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
13.12 Gabler Medical
13.12.1 Financial Analysis
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.12.5 Certifications
13.13 Sinapi Biomedical
13.13.1 Financial Analysis
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
13.13.5 Certifications
13.14 Church & Dwight
13.14.1 Financial Analysis
13.14.2 Product Portfolio
13.14.3 Demographic Reach and Achievements
13.14.4 Mergers and Acquisitions
13.14.5 Certifications
13.15 CooperSurgical
13.15.1 Financial Analysis
13.15.2 Product Portfolio
13.15.3 Demographic Reach and Achievements
13.15.4 Mergers and Acquisitions
13.15.5 Certifications
14 Africa Contraceptive Drugs and Devices Market - Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by the increased awareness among people.
The expanding healthcare infrastructure and the increased initiatives by the governments and non-profit organizations, such as WHO, are among the major factors driving the market growth.
The increasing awareness and demand for innovative developments for contraception is a major trend influencing the market growth.
Product categories include drugs and devices, among others. Drugs include oral contraceptive pills, injectable contraceptives, and topical contraceptives. Devices are divided into condoms, diaphragms, cervical caps, sponges, vaginal ring, and intra uterine devices (IUD), among others.
Based on gender, the market can divided into male and female.
Distribution channels include hospital pharmacies, retail pharmacies, clinics, online channels, public channels, and NGOs, among others.
Key players involved in the market are Merck & Co. Inc., Mylan N.V., Pfizer Inc., Bayer AG, AbbVie, Lupin Limited, Teva Pharmaceutical Industries Ltd, Medicines360, Durex, Mankind Pharma, Johnson & Johnson, Gabler Medical, Sinapi Biomedical, Church & Dwight, and CooperSurgical.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER